Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report.
Journal: European heart journal. Case reports
Published: June 30, 2024
Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension.
Journal: American journal of respiratory and critical care medicine
Published: October 13, 2018
Correction for Bagarova et al., "Constitutively Active ALK2 Receptor Mutants Require Type II Receptor Cooperation".
Journal: Molecular and cellular biology
Published: September 14, 2017
Incidence, Predictors, and Significance of Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices: A 15-Year Institutional Experience.
Journal: JACC. Clinical electrophysiology
Published: August 16, 2017
Type 4a myocardial infarction: Incidence, risk factors, and long-term outcomes.
Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
Published: January 27, 2016
Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension.
Journal: Pulmonary circulation
Published: September 10, 2013
Constitutively active ALK2 receptor mutants require type II receptor cooperation.
Journal: Molecular and cellular biology
Published: April 11, 2013
Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: January 07, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026